knowledge -WSS

knowledge

author：knowledge 2025-09-29 12:09:00 - browse：12368

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： FDA advisory panel to debate high blood pressure devices

hotspot

WSS

How Long Island became the ‘eugenics capital of the world’

Abortion policy in the spotlight at Republican debate

As pharma fights Medicare drug negotiation, hospitals, docs silent

PBMs are inflating the cost of generic drugs. They must be reined in

As pharma fights Medicare drug negotiation, hospitals, docs silent

As pharma fights Medicare drug negotiation, hospitals, docs silent

Wikipedia

knowledge

leisure time

Cancer drug shortages should be causing more outrage

People can get long Covid without testing positive for virus: Study

Hepatitis C has a cure — but many Americans still lack access to it

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Radiation, mainstay of cancer treatment, begins a fade

Wildfire smoke exposes gaps in outdoor worker protections

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Medicare proposal to cover medical devices draws a mixed reaction

What AAP's gender

knowledge

Neuroscience startup Neumora files for IPO

How to make AI work for medicine

As pharma fights Medicare drug negotiation, hospitals, docs silent

Winners, losers from Medicare’s list of drugs subject to price talks

PBMs are inflating the cost of generic drugs. They must be reined in

Health officials lay out plans to cope with respiratory virus season

hotspot

explore

explore

hotspot